InterCure Ltd. (INCR)
 NASDAQ: INCR · Real-Time Price · USD
 1.400
 +0.010 (0.72%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.390
 -0.010 (-0.69%)
  After-hours: Oct 30, 2025, 7:02 PM EDT
InterCure Revenue
InterCure had revenue of 130.01M ILS in the half year ending June 30, 2025, a decrease of -37.68%. This brings the company's revenue in the last twelve months to 243.12M, down -10.84% year-over-year. In the year 2024, InterCure had annual revenue of 238.85M, down -32.82%.
Revenue (ttm) 
 243.12M ILS
Revenue Growth 
 -10.84%
P/S Ratio 
 1.07
Revenue / Employee 
 759,759 ILS
Employees 
 320
Market Cap 
77.33M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 238.85M | -116.71M | -32.82% | 
| Dec 31, 2023 | 355.55M | -33.13M | -8.52% | 
| Dec 31, 2022 | 388.68M | 169.01M | 76.93% | 
| Dec 31, 2021 | 219.68M | 154.64M | 237.78% | 
| Dec 31, 2020 | 65.04M | 56.11M | 628.60% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| Eli Lilly and Company | 59.42B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
INCR News
- 22 days ago - InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire
- 5 weeks ago - InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands - GlobeNewsWire
- 6 months ago - InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PRNewsWire
- 9 months ago - InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - PRNewsWire
- 11 months ago - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PRNewsWire
- 1 year ago - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
- 1 year ago - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewsWire
- 1 year ago - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire